Literature DB >> 17970929

Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire.

Antonio Valero, Jordi Alonso, Ignacio Antepara, Eva Baró, Carlos Colas, Alfonso del Cuvillo, Montse Ferrer, Michael Herdman, Enrique Martí-Guadaño, Laura Monclús, Joaquim Mullol, Ana María Navarro-Pulido, Carlos Navas, Joaquim Sastre, M Baltasar, J Bartra, C Serrano, V Cardona, J A Castillo, M T Cerda, A Cistero, A Conejero, I Davila, C Escudero, E Hernandez, A Vereda, B Fernandez, J Mencia, J Fernández, J Florido, J Quiralte, P Guardia, T Malek, J Montoro, J C Orta, A Oehling, M J Pascual, B de la Parte, E Raga, N Rubira, S Ranea, P Rivas, J Serra, A Tabar.   

Abstract

OBJECTIVES: To develop and validate an instrument to measure health-related quality of life (HRQOL) specific to patients with allergic rhinitis (AR) and primarily for use in Spanish and Spanish-speaking populations.
METHODS: An initial item pool was generated from literature review, focus groups with AR patients, and consultations with clinical experts. Item reduction was performed using clinimetric and psychometric approaches after administration of the item pool to 400 AR patients. The resulting instrument's internal consistency, test-retest (2-4 weeks) reliability, known groups and convergent validity, and sensitivity to change were tested in a longitudinal, observational, multicenter study in 210 AR patients who also completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
RESULTS: The new questionnaire took a mean (SD) of 7.1 (5.4) minutes to answer. Floor and ceiling effects were less than 15% on all dimensions. Cronbach's alpha values and intraclass correlation coefficient values for six of the sevendimensions and the overall score exceeded 0.70. Statistically significant differences (P < 0.01) were observed on all ESPRINT-28 dimensions and the overall score between patients with mild (mean overall score 1.97, SD 0.99), moderate (mean overall score 2.78, SD 0.88), and severe AR (mean overall score 3.89, SD 0.87). Patients with persistent AR had worse scores (P < 0.05) on all dimensions than patients with intermittent AR. Correlations between the ESPRINT-28 and the RQLQ were generally as expected. Effect sizes for score changes between the two study visits ranged from 0.96 to 1.76 for individual dimensions and the overall score.
CONCLUSIONS: This new, Spanish-developed instrument to measure HRQOL in AR patients has shown good reliability, validity, and sensitivity to change. It has also proved easy to use and administer.

Entities:  

Mesh:

Year:  2007        PMID: 17970929     DOI: 10.1111/j.1524-4733.2007.00202.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

1.  A community-based approach to translating and testing cancer literacy assessment tools.

Authors:  Omara Rivera-Vásquez; Athur Mabiso; Adnan Hammad; Karen Patricia Williams
Journal:  J Cancer Educ       Date:  2009       Impact factor: 2.037

2.  Validation of the DECA criteria for allergic conjunctivitis severity and control.

Authors:  M Cesárea Sánchez-Hernández; Ana M Navarro; Joaquim Mullol; Antonio Valero; Carlos Colás; Alfonso Del Cuvillo; Joaquín Sastre
Journal:  Clin Transl Allergy       Date:  2020-10-23       Impact factor: 5.871

Review 3.  Comparative analysis of allergic rhinitis in children and adults.

Authors:  Adriana Izquierdo-Domínguez; Antonio L Valero; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

Review 4.  Impact of sleep as a specific marker of quality of life in allergic rhinitis.

Authors:  Vanesa González-Núñez; Antonio Luís Valero; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

5.  Effectiveness and Response Predictors of Omalizumab in Treating Patients with Seasonal Allergic Rhinitis: A Real-World Study.

Authors:  Tingting Ma; Hongtian Wang; Xueyan Wang
Journal:  J Asthma Allergy       Date:  2021-01-22

6.  Classic test and generalizability theories are both useful for cross-cultural adaptation of an allergic rhinitis health-related quality of life questionnaire.

Authors:  Juan José Yepes-Nuñez; Edison Morales Cardenas; Carolina Gómez-García; Madelen Manco Sepúlveda; Lina Marcela Martínez; Antonio Valero; Meghan M McConnell
Journal:  World Allergy Organ J       Date:  2021-11-29       Impact factor: 4.084

7.  Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments.

Authors:  Gesmar Rs Segundo; Fabíola A Gomes; Karla P Fernandes; Ronaldo Alves; Deise Ao Silva; Ernesto A Taketomi
Journal:  Biologics       Date:  2009-10-12

8.  Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy.

Authors:  A Roger; E Arcalá Campillo; M C Torres; C Millan; I Jáuregui; E Mohedano; S Liñan; P Verdu; N Rubira; M Santaolalla; P González; A Orovitg; E Villarrubia
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-11       Impact factor: 3.406

9.  Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort.

Authors:  R Muñoz-Cano; P Ribó; G Araujo; E Giralt; J Sanchez-Lopez; A Valero
Journal:  Clin Transl Allergy       Date:  2018-07-09       Impact factor: 5.871

10.  Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis.

Authors:  Joaquim Mullol; Iñaki Izquierdo; Kimihiro Okubo; Giorgio Walter Canonica; Jean Bousquet; Antonio Valero
Journal:  Clin Transl Allergy       Date:  2019-10-09       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.